


Curriculum Vitae

Name	Dong-Hoe Koo, M.D., Ph.D.	
Current Position & Affiliation	Associate Professor, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine	
Country	Republic of Korea	

Educational Background

2002 M.D., Kyung-Hee University College of Medicine, Seoul, Korea

2007 M.S., University of Ulsan College of Medicine, Seoul, Korea

2014 Ph.D., University of Ulsan College of Medicine, Seoul, Korea

Professional Experience

2002-2007	Internship/Residency, Internal Medicine, Asan Medical Center, Seoul, Korea
2007-2010	International Doctor (Military service), Korea International Cooperation Agency (KOICA) Kampong-Cham Referral Hospital, Kampong-Cham, Cambodia
2010-2011	Fellowship in Oncology, Asan Medical Center, Seoul, Korea
2011-2012	Fellowship in Hematology/Oncology, Kangbuk Samsung Hospital, Seoul, Korea
2012-Current	Assistant/Associate Professor, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
2016-2017	Visiting Scientist, Baltimore, MD, USA
2019-Current	Chief, Division of Hematology/Oncology, Kangbuk Samsung Hospital, Seoul, Korea

Professional Organizations

Korean Cancer Association (KCA), General Affairs Committee
Korean Cancer Study Group (KCSG), Deputy Director for General Affairs
Korean Society of Medical Oncology (KSMO), Scientific & International Cooperation Committee
Korean GIST Study Group (KGSG), Planning Director
Korean Gastric Cancer Association (KGCA), Scientific & Planning Committee
Korean Ministry of Food and Drug Safety (MFDS), Central Pharmaceutical Affairs Review Committee
American Society of Clinical Oncology (ASCO), Member

Main Scientific Publications (Recent 3-year publications)

Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer Over a 16-year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. *Cancer Res Treat.* 2021 Apr;53(2):436-444.

Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology. Bae G, Bae S, Lee D, Han J, **Koo DH**, Kim DY, Kim HJ, Oh SY, Lee HY, Lee JH, Han HS, Ha H, Kang JH. *Int J Environ Res Public Health.* 2021 Mar 18;18(6):3139.

Hwang IG, Kwon M, Kim JW, Kim SH, Lee YG, Kim JY, Koh SJ, Ko YH, Shin SH, Hong S, Kim TY, Kim SY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Lee KH, Bae SH, **Koo DH**, Kim JH, Woo IS. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. *Cancers (Basel).* 2021 Jan 18;13(2):331.

Do IG, Jung KU, **Koo DH***, Lee YG, Oh S, Kim K, Kim DH, Sohn JH, Son BH, Lee SR, Shin JH, Kim HO, Kim H, Chun HK, Serrero G, Yoo CH. Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progranulin expression. *PLoS One.* 2021 Jan 7;16(1):e0245153. (*Corresponding author)

Kim MS, Hong HP, Ham S-Y, **Koo DH**, Kang D-Y, et al. (2020) Complications after 100 sessions of cone-beam computed tomography-guided lung radiofrequency ablation: a single-center, retrospective experience. *Int J Hyperthermia*. 2020 Jul; 37: 763-771.

Kim K, Huh T, Park Y, **Koo DH**, Kim H, Hwang I, Choi CH, Yi JM, Chung JY. Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. *Pathol Res Pract*. 2020 Jun;216(6):152988.

Kang JH, Kwon JH, Lee YG, Park KU, An HJ, Sohn J, Seol YM, Lee H, Yun HJ, Ahn JS, Yang JH, Song H, **Koo DH**, Kim JY, Kim GM, Kim HJ. Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. *Cancer Res Treat*. 2020 Jul;52(3):907-916.

Koo DH, Han KD, Kim HJ, Park CY. Middle-Aged Men with Type 2 Diabetes as Potential Candidates for Pancreatic Cancer Screening: A 10-Year Nationwide Population-Based Cohort Study. *Acta Diabetol*. 2020 Feb; 57 (2), 197-202.

Koo DH, Do IG, Oh S, Lee YG, Kim K, Sohn JH, et al. Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. *Pathol Oncol Res*. 2020 Jan;26(1):397-404.

Kang J, Chang Y, Ahn J, Oh S, **Koo DH**, Lee YG, Shin H, Ryu S. Neutrophil-to-lymphocyte Ratio and Risk of Lung Cancer Mortality in a Low-Risk Population: A Cohort Study. *Int J Cancer*. 2019 Dec; 145 (12), 3267-3275.

Koo DH, Han KD, Park CY. The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study. *J Clin Endocrinol Metab*. 2019 Oct; 104 (10), 4594-4599.

Lee YG, Chang Y, Kang J, **Koo DH**, Lee SS, Ryu S, Oh S. Risk factors for incident anemia of chronic diseases: A cohort study. *PLoS One*. 2019 May;14(5):e0216062.

Lee YG, Jung I, **Koo DH**, Kang DY, Oh TY, Oh S, Lee SS. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer. 2019 May;27(5):1945-1949.

Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. J Gastric Cancer. 2019 Mar;19(1):1-48.

Kim JW, Kim JG, Kang BW, Chung IJ, Hong YS, Kim TY, Song HS, Lee KH, Zang DY, Ko YH, Song EK, Baek JH, **Koo DH**, et al. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Res Treat. 2019 Jan;51(1):223-239.
